163671-48-5

Basic information

• Product Name: Cyclohexanone, 4-(4-ethoxyphenyl)- (9CI)
• Synonyms: Cyclohexanone, 4-(4-ethoxyphenyl)- (9CI);4-(4-Ethoxyphenyl)cyclohexanone
• CAS NO: 163671-48-5
• Molecular Formula: C₁₄H₁₈O₂
• Molecular Weight: 218.29152
• Product Categories: ETHOXY
• Mol File: 163671-48-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 349.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.051±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Cyclohexanone, 4-(4-ethoxyphenyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanone, 4-(4-ethoxyphenyl)- (9CI)(163671-48-5)
• EPA Substance Registry System: Cyclohexanone, 4-(4-ethoxyphenyl)- (9CI)(163671-48-5)

Safety Data

• Hazardous Substances Data: 163671-48-5(Hazardous Substances Data)

Upstream product

• 64-67-5 diethyl sulfate 
• 105640-07-1 4-(4-hydroxyphenyl)cyclohexan-1-one 
• 75-03-6 ethyl iodide 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 163671-46-3 8-(4-ethoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol 
• 163671-47-4 8-(4-ethoxy-phenyl)-1,4-dioxa-spiro[4.5]decane 

Downstream Products

• 868142-37-4 8-(4-ethoxy-phenyl)-2,4-dioxo-1,3-diaza-spiro[4.5]decane-1,3-dicarboxylic acid di-tert-butyl ester 
• 868142-10-3 8-(4-ethoxy-phenyl)-1,3-diaza-spiro[4.5]decane-2,4-dione 

Relevant articles and documents

Synthesis method of 4-substituent cyclohexanone liquid crystal intermediate

The invention discloses a synthesis method of a 4-substituent cyclohexanone liquid crystal intermediate, which comprises the following step: carrying out oxidation catalytic reaction on 4-substituent cyclohexanol under the action of trichloroisocyanide urea to obtain the 4-substituent cyclohexanone liquid crystal intermediate. The method is high in reaction selectivity, high in yield, environment-friendly, simple in post-treatment and suitable for industrial production.

Piperazine structure containing four tetrahydrobenz [4, 5] thieno [2, 3 - d] pyrimidine compound and use thereof

The invention belongs to the technical field of medicine, and relates to piperazine-structure-containing tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine compounds and application thereof as an epidermal growth factor receptor tyrosine kinase inhibitor, and a preparation method of the compounds. The piperazine-structure-containing tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine compounds and pharmaceutically acceptable salts thereof, and a pharmaceutically compatibility-acceptable carrier or diluter can be used as an epidermal growth factor receptor tyrosine kinase inhibitor. The structural general formula is disclosed in the specification, wherein R1, R2 and R3 are disclosed in the specification. The compounds are simple in synthesis method and suitable for industrial production. The bioactivity test shows that the compounds have the activity of inhibiting epidermal growth factor, human lung cancer cell strain A549, human oophoroma cell strain SKOV3 and human osteosarcoma cell U2OS-EGFP-4A12G, and are an epidermal growth factor receptor tyrosine kinase inhibitor with antitumor function.

Discovery of 1-amino-4-phenylcyclohexane-1-carboxylic acid and its influence on agonist selectivity between human melanocortin-4 and -1 receptors in linear pentapeptides

Linear pentapeptides (Penta-cis-Apc-DPhe-Arg-Trp-Gly-NH2) containing 1-amino-4-phenylcyclohexane-1-carboxylic acid (cis-Apc) and substituted Apc are potent hMC4R agonists and they are inactive or weakly active in hMC1R, hMC3R, and hMC5R agonist assays. This study, together with our earlier report on 5-BrAtc, demonstrated the importance of replacing His 6 with phenyl-containing rigid templates in achieving good hMC4R agonist potency and selectivity against hMC1R in linear pentapeptides.